

Our ref: FOI 1141

26<sup>th</sup> July 2022

**FOI 1141 RESPONSE**

**1) In total, over the past 4 months, how many patients have been treated for the following diseases (Rheumatoid arthritis, Axial Spondyloarthritis, Psoriatic arthritis, Psoriasis, hidradenitis suppurativa)?**

Rheumatoid arthritis	522
Axial Spondyloarthritis	43
Psoriatic arthritis	380
Psoriasis	407
Hidradenitis suppurativa	43

**2) Of these five, how many of each received the following products:**

- Adalimumab (Humira)
- Adalimumab Biosimilar
- Etanercept (Enbrel)
- Etanercept Biosimilar
- Infliximab (Remicade)
- Infliximab biosimilar
- Golimumab (Simponi)
- Tofacitinib (Xeljanz)
- Ustekinumab (Stelara)
- Vedolizumab (Entyvio)
- Filgotinib (Jyseleca)
- Abatacept (Orencia)
- Baricitinib (Olumiant)
- Certolizumab Pegol (Cimzia)
- Rituximab (MabThera)
- Rituximab Biosimilar
- Tocilizumab (RoActemra)
- Sarilumab (Kevzara)
- Apremilast (Otezla)
- Secukinumab (Cosentyx)
- Isekizumab (Taltz)
- Guselkumab (Tremfya)
- Brodalumab (Kyntheum)
- Risankizumab (Skyrizi)
- Tildrakizumab (Ilumetri)
- Upadacitinib (Rinvoq)

- Bimekizumab (Bimzelx)

	RA	AX SPON	PsA	PSO	HS
Adalimumab (Humira)	7	<5	16	9	19
Adalimumab Biosimilar	120	16	142	168	19
Etanercept (Enbrel)	12	0	<5	0	0
Etanercept Biosimilar	73	<5	58	<5	0
Infliximab (Remicade)	0	0	0	0	0
Infliximab biosimilar	9	<5	11	<5	<5
Golimumab (Simponi)	19	5	29	0	0
Tofacitinib (Xeljanz)	8	0	7	0	0
Ustekinumab (Stelara)	0	0	0	36	0
Vedolizumab (Entyvio)	0	0	0	0	0
Filgotinib (Jyseleca)	0	0	0	0	0
Abatacept (Orencia)	76	<5	<5	0	0
Baricitinib (Olumiant)	57	0	0	0	0
Certolizumab Pegol (Cimzia)	13	13	27	5	0
Rituximab (MabThera)	0	0	0	0	0
Rituximab Biosimilar	86	0	0	0	0
Tocilizumab (RoActemra)	22	0	<5	0	0
Sarilumab (Kevzara)	9	0	0	0	0
Apremilast (Otezla)	0	0	0	0	0
Secukinumab (Cosentyx)	<5		69	30	<5
Isekizumab (Taltz)	<5	<5	13	42	0
Guselkumab (Tremfya)	0	0	0	60	0
Brodalumab (Kyntheum)	0	0	0	10	0
Risankizumab (Skyrizi)	0	0	0	27	0
Tildrakizumab (Ilumetri)	0	0	0	14	0
Upadacitinib (Rinvoq)	9	0	<5	0	0
Bimekizumab (Bimzelx)	0	0	0	0	0

**3) Could you please provide the number of these patients that were treated within the gastro department (still split by disease and treatment).**

None of these patients are under Gastro

**4) Over the same time period, how many patients for each of the five diseases (Rheumatoid arthritis, Axial Spondyloarthritis, Psoriatic arthritis, Psoriasis, hidradenitis suppurativa) received the following treatments as their first ever biologic treatment?**

- **AxSPA**
- **PsA**
- **PsO**

Listed options are not treatments therefore 0 patients

The Trust has a legal duty to protect patient confidentiality and, in line with this duty, the figure <5 has been provided where figures are very low. This is because of the potential risk of identification of an individual. In reaching this decision the Trust has taken into account the small geographical area which the Trust serves and the sensitivity of the information requested. In addition the Trust has taken into account the fact that all information disclosed in response to an FOI is disclosed to the 'world at large' and is published on the Trust website.

S 40 (2) (third party information) of the Freedom of Information Act 2000 has been applied to exempt the redacted information from disclosure. The Trust does not consider the disclosure of the redacted information to be fair to the individuals concerned as there is the potential risk of identification of an individual(s) which they would not expect, and which would therefore breach the fairness element of the first principle of the Data Protection Act 2018.

Contact: [FOI.team@southerntrust.hscni.net](mailto:FOI.team@southerntrust.hscni.net)